Raw Ground Truth
Inclusion CriteriaEastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following:.i) Autologous stem cell transplant (ASCT) ineligible patients.ii) Patients after failure of ASCT.- Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.Exclusion CriteriaKnown central nervous system lymphoma.Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL).Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML).Other protocol-defined Inclusion/Exclusion criteria apply.
Raw Prediction
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
- Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following:
i) Autologous stem cell transplant (ASCT) ineligible patients.
ii) Patients after failure of ASCT.
- Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.
- Participants must not have received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody.
Exclusion Criteria:
- Known central nervous system lymphoma.
- Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL).
- Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML).
- Participants with evidence of active brain metastases on brain imaging (i.e., MRI or contrast CT).
- Participants who have received prior allogeneic transplant.
- Participants who are BV refractory as identified by a failure to achieve a PR or CR, relapse, or progression within 3 months of receiving BV treatment.
- Participants with any positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus.
- Participants with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- Participants who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
- Females who are pregnant or breastfeeding.
Processed Ground Truth
1. Inclusion CriteriaEastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
2. Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following:.i) Autologous stem cell transplant (ASCT) ineligible patients.ii) Patients after failure of ASCT.- Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.
3. Exclusion CriteriaKnown central nervous system lymphoma.
4. Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL).
5. Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML).
6. Other protocol-defined Inclusion/Exclusion criteria apply.
Processed Prediction
1. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
2. Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following:
3. i) Autologous stem cell transplant (ASCT) ineligible patients.
4. ii) Patients after failure of ASCT.
5. Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.
6. Participants must not have received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody.
1. Known central nervous system lymphoma.
2. Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL).
3. Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML).
4. Participants with evidence of active brain metastases on brain imaging (i.e., MRI or contrast CT).
5. Participants who have received prior allogeneic transplant.
6. Participants who are BV refractory as identified by a failure to achieve a PR or CR, relapse, or progression within 3 months of receiving BV treatment.
7. Participants with any positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus.
8. Participants with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
9. Participants who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
10. Females who are pregnant or breastfeeding.